Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Lymphoid 1

Conditions

Multiple Myeloma 4Vascular Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1Glioma 1Glioblastoma 1Fibrosarcoma 1

Interventions

Dexamethasone 44Lenalidomide 29Bortezomib 23daratumumab 22pomalidomide 19Cyclophosphamide 15carfilzomib 14Specimen Handling 14Biopsy 14Calcium Dobesilate 12Magnetic Resonance Spectroscopy 10talquetamab 9isatuximab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5tocilizumab 4selinexor 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × selinexor × 30 days × Clear all
NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06822972 2026-06-04

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Duke University

Phase 2 Recruiting
27 enrolled
Plasma cell

Multiple Myeloma

NCT04640779 2026-05-28

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1 Completed
22 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
228 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡